Emerging options for the treatment of melanoma – focus on ipilimumab

References

• MillerAJMihmMCJrMelanomaN Engl J Med20063551516516822996
   PubMed Web of Science ®Google Scholar
• International Agency for Research on CancerThe GLOBOCAN project [homepage on the Internet]Geneva, SwitzerlandWorld Health Organization2010 Available from: http://globocan.iarc.frAccessed January 12, 2013
   Google Scholar
• National Cancer InstituteSEER stat fact sheets: melanoma of the skin [webpage on the Internet]Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/statfacts/html/melan.htmlAccessed January 12, 2013
   Google Scholar
• KornELLiuPYLeeSJMeta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol200826452753418235113
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteMelanoma treatment (PDQ) [webpage on the Internet]Bethesda, MDNational Cancer Institute52013 Available from: http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page4Accessed on August 26, 2013
   Google Scholar
• American Cancer SocietyDetailed guide on treatment of melanoma by stage Available at: http://www.cancer.org/cancer/skin-cancer-melanoma/detailedguide/melanoma-skin-cancer-treating-by-stageAccessed August 26, 2013
   Google Scholar
• FrickerJNew era in metastatic melanomaMol Oncol2010419197
   Web of Science ®Google Scholar
• QuirbtIVermaSPetrellaTBakKCharetteMfor Members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based CareTemozolomide for the treatment of metastatic melanomaCurr Oncol2007141273317576461
   PubMedGoogle Scholar
• AgarwalaSSCurrent systemic therapy for metastatic melanomaExpert Rev Anticancer Ther20099558759519445576
   PubMed Web of Science ®Google Scholar
• PatelPMSuciuSMortierLfor EORTC Melanoma GroupExtended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Eur J Cancer201147101476148321600759
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• BrunetJFDenizotFLucianiMFA new member of the immunoglobulin superfamily – CTLA-4Nature198732861272672703496540
   PubMed Web of Science ®Google Scholar
• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• van ElsasAHurwitzAAAllisonJPCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med1999190335536610430624
   PubMed Web of Science ®Google Scholar
• KirkwoodJMTarhiniAAPanelliMCNext generation of immunotherapy for melanomaJ Clin Oncol200826203445345518612161
   PubMed Web of Science ®Google Scholar
• HurwitzAAFosterBAKwonEDCombination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockadeCancer Res20006092444244810811122
   PubMed Web of Science ®Google Scholar
• ParadisTJFloydEBurkwitJThe anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gammaCancer Immunol Immunother200150312513311419179
   PubMed Web of Science ®Google Scholar
• GrazianiGTentoriLNavarraPIpilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancerPharmacol Res201265192221930211
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb CompanyIpilimumab US Prescribing Information 2011Princeton, NJBristol-Myers Squibb Company2012 Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdfAccessed on January 12, 2013
   Google Scholar
• YERVOY 5 mg/mL concentrate for solution for infusion – Summary of Product Characteristics (SPC) [webpage on the Internet]Electronic Medicines Compendium2013 Available from: http://www.medicines.org.uk/emc/medicine/24779Accessed on January 12, 2013
   Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
   PubMed Web of Science ®Google Scholar
• Di GiacomoAMAsciertoPAPillaLIpilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialLancet Oncol201213987988622894884
   PubMed Web of Science ®Google Scholar
• PatelSPHwuWJKimKBPhase II study of the frontline combination of ipilimumab and temozolamide in patients with metastatic melanoma [abstract]J Clin Oncol2012Suppl8514
   Google Scholar
• PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
   PubMed Web of Science ®Google Scholar
• MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnn Surg Oncol200512121005101616283570
   PubMed Web of Science ®Google Scholar
• BernardoSGMoskalenkoMPanMElevated rates of transaminitis during ipilimumab therapy for metastatic melanomaMelanoma Res2013231475423262440
   PubMed Web of Science ®Google Scholar
• HamidOSchmidtHNissanAA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJ Transl Med2011920422123319
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• RetsasSLatest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?J R Soc Med2011104626927221659402
   PubMed Web of Science ®Google Scholar
• MargolinKIpilimumab in a Phase II trial of melanoma patients with brain metastasesOncoimmunology2012171197119923170278
   PubMed Web of Science ®Google Scholar
• FonkemEUhlmannEJFloydSRMelanoma brain metastasis: overview of current management and emerging targeted therapiesExpert Rev Neurother201212101207121523082737
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• KhattakMAFisherRHughesPGoreMLarkinJIpilimumab activity in advanced uveal melanomaMelanoma Res2013231798123211837
   PubMed Web of Science ®Google Scholar
• KhanKDCallahanMPostowMAEfficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations [abstract]J Clin Oncol2012Suppl8511
   Google Scholar
• DanielliRRidolfiRChiarion-SileniVIpilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyCancer Immunol Immunother2012611414821833591
   PubMed Web of Science ®Google Scholar
• CulverMEGatesmanMLManclEELoweDKIpilimumab: a novel treatment for metastatic melanomaAnn Pharmacother201145451051921505108
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity1995355415477584144
   PubMed Web of Science ®Google Scholar
• WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol201230212691269722614989
   PubMed Web of Science ®Google Scholar
• Bristol-Myers SquibbIpilimumab US prescribing information: risk evaluation and mitigation strategy [webpage on the Internet]Princeton, NJBristol-Meyers Squibb2012 Available from: http://www.yervoy.com/hcp/rems.aspxAccessed January 12, 2013
   Google Scholar
• TrinhVAHagenBIpilimumab for advanced melanoma: A pharmacologic perspectiveJ Oncol Pharm Pract Epub10112012
   Google Scholar
• WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaClin Cancer Res200915175591559819671877
   PubMed Web of Science ®Google Scholar
• Gaudy-MarquesteCMonestierSFranquesJCantaisERichardMAGrobJJA severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitisJ Immunother2013361777823211620
   PubMed Web of Science ®Google Scholar
• AminADePrilVHamidOEvaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity [abstract]J Clin Oncol200927Suppl 159037
   Web of Science ®Google Scholar
• PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A2003100148372837712826605
   PubMed Web of Science ®Google Scholar
• JohnstonRLLutzkyJChodhryABarkinJSCytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximabDig Dis Sci200954112538254019104936
   PubMed Web of Science ®Google Scholar
• YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJ Immunother200730882583018049334
   PubMed Web of Science ®Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol2013241758322858559
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDfor IMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• SmallEJTchekmedyianNSRiniBIFongLLowyIAllisonJPA pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerClin Cancer Res20071361810181517363537
   PubMed Web of Science ®Google Scholar
• van den EertweghAJVersluisJvan den BergHPCombined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550951722326922
   PubMed Web of Science ®Google Scholar
• MadanRAMohebtashMArlenPMIpilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550150822326924
   PubMed Web of Science ®Google Scholar
• RoyalRELevyCTurnerKPhase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinomaJ Immunother201033882883320842054
   PubMed Web of Science ®Google Scholar
• AnsellSMHurvitzSAKoenigPAPhase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphomaClin Cancer Res200915206446645319808874
   PubMed Web of Science ®Google Scholar
• HodiFSMihmMCSoifferRJBiologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProc Natl Acad Sci U S A200310084712471712682289
   PubMed Web of Science ®Google Scholar
• CornishDHolterhuesCvan de Poll-FranseLVCoeberghJWNijstenTA systematic review of health-related quality of life in cutaneous melanomaAnn Oncol200920Suppl 6vi51vi5819617298
   PubMed Web of Science ®Google Scholar
• TraskPCPatersonAGEsperPPauJRedmanBLongitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferonPsychooncology200413852653615295774
   PubMed Web of Science ®Google Scholar
• BoyleDAPsychological adjustment to the melanoma experienceSemin Oncol Nurs2003191707712638383
   PubMedGoogle Scholar
• CohenLParkerPASternerJDe MoorCQuality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumor-derived vaccineMelanoma Res200212550551112394193
   PubMed Web of Science ®Google Scholar
• SpecenierPIpilimumab in melanomaExpert Rev Anticancer Ther201212121511112123181437
   PubMed Web of Science ®Google Scholar
• NICE guideline: Melanoma (stage III or IV)- Ipilimumab: guidance [webpage on the Internet] Available from: http://guidance.nice.org.uk/TA268/Guidance/pdf/EnglishAccessed November 21, 2013
   Google Scholar
• QuezadaSAPeggsKSCurranMAAllisonJPCTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJ Clin Invest200611671935194516778987
   PubMed Web of Science ®Google Scholar
• LiakouCIKamatATangDNCTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patientsProc Natl Acad Sci U S A200810539149871499218818309
   PubMed Web of Science ®Google Scholar
• FuTHeQSharmaPThe ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapyCancer Res201171165445545421708958
   PubMed Web of Science ®Google Scholar
• Di GiacomoAMCalabròLDanielliRLong-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programmeCancer Immunol Immunother Epub4172013
   Web of Science ®Google Scholar